Research Article

Effects of Preexisting Psychotropic Medication Use on a Cohort of Patients with Ischemic Stroke Outcome

Table 2

Patient characteristics.

CharacteristicsPrepsychotropic use ()Non-PPMU (control +PoMU) ()Unadjusted value

Gender, female47 (68.1%)95 (37.4%)<0.001
Age66 (57-76)67 (58-78)0.443
Admission NIHSS3 (1-8.5)3 (1-7)0.352
MRS on index presentation0 (0-2)0 (0-0)<0.001
IV tPA on index presentation12 (17.4%)62 (24.4%)0.26
Thrombectomy9 (13.0%)25 (9.8%)0.442
Decompressive craniectomy1 (1.4%)7 (2.8%)0.536
Length of stay4 (3-7.5)4 (3-7)0.731
Stroke volume (ml)1.4 (1.0-7.0)1.6 (1.0-13)0.312
Discharge destination0.343
 Home32 (46.4%)115 (45.3%)
 Acute rehab26 (37.7%)113 (44.5%)
 Skilled nursing facility11 (15.9%)26 (10.2%)
Preexisting risk factors
 HTN51 (73.9%)177 (69.7%)0.494
 Dyslipidemia47 (68.1%)155 (61.0%)0.280
 DM23 (33.3%)75 (29.5%)0.542
 History of TIA/stroke23 (33.3%)66 (26.0%)0.226
Atrial fibrillation8 (11.6%)49 (19.3%)0.137
 CAD16 (23.2%)54 (21.3%)0.730
 PVD14 (20.3%)46 (18.1%)0.680
Preadmission medications
 Statins42 (60.9%)121 (47.6%)0.051
 Antihypertensives47 (68.1%)156 (61.4%)0.307
 Antidiabetics17 (24.6%)58 (22.8%)0.753
 Antiplatelet31 (44.9%)122 (48.0%)0.647
 Anticoagulation5 (7.2%)18 (7.1%)0.964
Lesion side0.756
 Right31 (44.9%)12 (44.1%)
 Left30 (43.5%)103 (40.6%)
 Both7 (10.1%)29 (11.4%)
Lesion circulation0.001
 Anterior46 (66.7%)143 (56.3%)
 Posterior13 (18.8%)95 (37.4%)
 Both9 (13.0%)7 (2.8%)
 Hemorrhagic conversion6 (8.7%)22 (8.7%)0.993

Data are median (IQ range) and n (%).